- Face time is policy: Appointment logs for USTR officials Froman, Holleyman and Punke, through July 2016
- KEI December 2, 2016 meeting on the delinkage of R&D costs from drug prices
- KEI Comments on NIH Proposed Exclusive License to Kite Pharma for Cancer Treatment
- Kite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute
- Kite Pharma Uses CRADAs to Conduct Important Clinical Research on New Cancer Treatments
- 17 October 2016: USTR Ambassador Michael Froman's reflections on the United Nations High-Level Panel on Access to Medicines
- 56 NGOs ask US Government enable export of low cost generic versions Xtandi to developing countries
- 5 October 2016: Statement of Knowledge Ecology International at inaugural Marrakesh Treaty Assembly
- KEI statement at WIPO GA 2013 on the Inter-governmental Committee (IGC) on genetic resources, traditional knowledge
- WIPO GA 2016: Statement by India on behalf of Asia Pacific Group - Report on the IGC
5 questions about NIH licenses to patents on Production of Attenuated Respiratory Syncytial Virus VaccinesSubmitted by James Love on 22. February 2016 - 0:59
The NIH has a notice for comments on proposed licenses of several patents relating to the "Production of Attenuated Respiratory Syncytial Virus Vaccines". See: https://federalregister.gov/a/2016-03486
We asked Peter Soukas, a Senior Technology Licensing Specialist in the Technology Transfer and Intellectual Property Office, at the National Institute of Allergy and Infectious Diseases (NIAID), these questions:
- What provisions exist in the license to protect US residents against excessive or unreasonable pricing?
Submission of Knowledge Ecology International
U.S. Copyright Office Docket No. 2015-6
This is the submission of Knowledge Ecology International (KEI) in response to the U.S. Copyright Office request for public comment on “software-enabled consumer products” (U.S. Copyright Office Docket No. 2015-6).
Knowledge Ecology International is a non-governmental organization with offices in Washington, DC, and Geneva, Switzerland, that searches for better outcomes, including new solutions, to the management of knowledge resources.
This submission covers these topics:
Obama Administration Recommends Senate Ratify Marrakesh Treaty for the Blind; Implementation Language Would Limit ExportsSubmitted by Claire Cassedy on 12. February 2016 - 14:35
CONTACT: Zack Struver
+1 (202) 332-2670
Obama Administration Recommends Senate Ratify Marrakesh Treaty for the Blind; Implementation Language Would Seriously Limit Exports
WTO TRIPS Council (March 2016) to discuss Intellectual Property and Innovation: Education and DiffusionSubmitted by thiru on 12. February 2016 - 12:47
The World Trade Organization (WTO) will convene its Council for TRIPS (TRIPS Council) from Tuesday, 1 March 2016 to Wednesday, 2 March 2016. Australia, the European Union, Switzerland and the United States of America have submitted a written request for the item "Intellectual Property and Innovation: Education and Diffusion" to be placed on the proposed agenda.
5 FEBRUARY 2016
SUBJECT: COUNCIL FOR TRIPS
THE NEXT MEETING OF THE COUNCIL FOR TRIPS WILL BE HELD IN THE CENTRE WILLIAM RAPPARD ON 1-2 MARCH 2016. THE MEETING WILL START AT
This is the announcement.
For Immediate Release February 10, 2016
TO THE SENATE OF THE UNITED STATES:
With a view to receiving the advice and consent of the Senate to ratification, I transmit herewith the Marrakesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually Impaired, or Otherwise Print Disabled, done at Marrakesh on June 27, 2013 (Marrakesh Treaty). I also transmit, for the information of the Senate, a report of the Secretary of State with respect to the Marrakesh Treaty that includes a summary of its provisions.
USPTO White Paper Suggests Statutory Factors To Clarify Extent of Statutory Damages for Copyright InfringementSubmitted by Salvatore Angotti on 10. February 2016 - 14:13
By Salvatore Angotti*
On February 8, 2016, the National Institutes of Health (NIH) responded to Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment’s (UACT) letter requesting that the federal government exercise its authority under the Bayh-Dole Act to break patents on an expensive prostate cancer drug.
In May 2014, the 67th World Health Assembly (WHA) of the World Health Organization (WHO) passed Decision WHA67(15) providing WHO the mandate to explore the feasibility of creating a voluntary pooled fund fund on R&D hosted by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). The Decision outlined three principles guiding the consideration of the pooled fund:
Implications of the Trans Pacific Partnership (TPP) and Regional Comprehensive Economic Partnership (RCEP) on Universal Health Coverage
Knowledge Ecology International
26 January 2016
9 AM to 12:30 PM
Lotus Suite 3. 22nd Floor
Bangkok Convention Centre
Today Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) petitioned the Department of Health and Human Services, the Department of Defense, and the National Institutes of Health, asking that they exercise either their royalty-free, non-exclusive license or federal "march-in" rights to end the monopoly on an expensive prostate cancer drug, enzalutamide, marketed as Xtandi by Astellas, a Japanese pharmaceutical company.
Xtandi was invented at UCLA on federal grants from the NIH and DoD.
Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutesSubmitted by KEI Staff on 13. January 2016 - 11:14
Washington, DC — On January 11, 2016, Knowledge Ecology International joined Public Knowledge and the American Library Association in an amicus curiae brief that argued that the contents of model laws, once enacted into statute, cannot be protected by copyright. The brief was filed with the U.S. District Court for the District of Columbia in the case of ASTM International v. Public.Resource.Org.
This was the release from Representative Doggett's office:
FOR IMMEDIATE RELEASE
January 11, 2016
Leslie Tisdale, (202) 225-4865
Over 50 Members of Congress to Obama Administration:
Help End Drug Price Gouging Now
WHO's evaluation of the global strategy and plan of action on public health, innovation and intellectual propertySubmitted by thiru on 11. January 2016 - 4:36
In May 2008, the 61st World Health Assembly (WHA) of the World Health Organization (WHO) adopted the seminal global strategy and plan of action on public health, innovation and intellectual property.
As stated in its aim, the global strategy on public health, innovation and intellectual property serves to
In calendar year 2015, FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs). This is a large number of approvals.
Attached here is a KEI submission to the US ITC for the January hearing of the
UNITED STATES INTERNATIONAL TRADE COMMISSION
Investigation No. TPA-105-001
Trans-Pacific Partnership Agreement: Likely Impact on the U.S. Economy and on Specific Industry Sectors
Our earlier, related testimony on trade agreements was here: http://keionline.org/node/2370